Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 599.40, up by 9.35 points or 1.58% from its previous closing of Rs. 590.05 on the BSE.

The scrip opened at Rs. 599.95 and has touched a high and low of Rs. 602.90 and Rs. 594.80 respectively. So far 12854 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 703.95 on 25-Aug-2016 and a 52 week low of Rs. 390.00 on 29-Mar-2016.

Last one week high and low of the scrip stood at Rs. 642.20 and Rs. 558.00 respectively. The current market cap of the company is Rs. 10446.27 crore.

The promoters holding in the company stood at 51.28%, while Institutions and Non-Institutions held 25.89% and 22.83% respectively.

Natco Pharma has received final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for generic version of Budesonide Capsules (Enteric Coated), 3 mg. The pharma major and its marketing partner Alvogen plan to launch this product in the USA market immediately.

Perrigo Pharma International DAC sells Budesonide Capsules under their brand ENTOCORT in the USA market. ENTOCORT EC Capsules, 3 mg and its generic versions had US sales of approximately $ 370 million for twelve months ending December 2015, as per IMS Health.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.